Novavax (NVAX) Q3 2025 Earnings Transcript

Novavax reported Q3 revenue of $70 million versus $85 million a year ago, but raised its 2025 adjusted total revenue framework to $1.040 billion-$1.060 billion and reaffirmed gross R&D plus SG&A guidance at $505 million-$535 million. The company completed the Sanofi commercial transition, earned $225 million in 2025 milestones, and ended the quarter with $812 million in cash and receivables, while also outlining 2026 revenue of $185 million-$205 million and non-GAAP profitability now targeted as early as 2028. Cost cuts and restructuring benefits from the Maryland campus consolidation support the balance sheet, but the delayed CIC timeline and lower COVID prescription trends remain headwinds.

Analysis

The key market implication is not the headline revenue decline; it is that NVAX is becoming an option on partner execution rather than a standalone vaccine commercial story. That usually compresses operating risk over time, but it also makes the equity more path-dependent on a smaller number of binary milestones, which can create sharper rerating and de-rating swings around partner updates than the market currently prices.

Sanofi is the real operating leverage vector here. If Sanofi converts transition-year activity into durable U.S./EU contracting discipline and later CIC advancement, NVAX’s revenue mix can shift from reimbursement-heavy to royalty-heavy with much better margin visibility; if not, the 2028 profitability path slips again and the stock will likely re-rate down on duration, not just earnings. The market may be underestimating how much of the current valuation is effectively funded by non-dilutive capital and asset monetization rather than recurring franchise economics.

The contrarian issue is that the “leaner” cost base is simultaneously a sign of progress and a sign of narrowing strategic flexibility. Cutting SG&A and campus costs improves survival odds, but it also reduces the company’s ability to self-correct if partner timelines slow or if a pipeline asset disappoints; in that scenario, optionality gets preserved on paper but not monetized in time. That makes the near-term setup asymmetric: good partner news can move the stock quickly, but bad timing news can overwhelm the lower burn story because the path to self-funding remains several quarters away.

Relative winners are SNY, which gets an asset-light commercialization model with embedded upside, and arguably other adjuvant/vaccine platform peers if Matrix-M continues to validate as a licensing tool. The clearer losers are mRNA/COVID incumbents if U.S. uptake stays structurally softer and “season-reset” behavior keeps demand below prior assumptions; the bigger second-order effect is that pharmacies and distributors may further rationalize inventory across the category, pressuring spot supply assumptions into the next season.

Key Decisions for Investors

• Long NVAX / short MRNA into the next 1-3 months: NVAX has cleaner idiosyncratic catalysts from Sanofi milestones and cost-out, while MRNA still faces category demand normalization; use a 1.5-2.0x downside stop on the spread if vaccine sentiment improves broadly.
• Buy NVAX call spreads 6-9 months out, centered just above current levels: the thesis is milestone-driven upside with limited carry, but cap risk because any delay in CIC timing can reprice 2026-2027 revenue expectations quickly.
• Pair long SNY vs short PFE over 3-6 months: SNY has the more credible embedded optionality from Novavax partnership economics and pandemic-flu Matrix-M expansion, while PFE remains more exposed to normalization in vaccine demand and capital allocation drag.
• Avoid outright short NVAX here: the balance sheet and nondilutive cash reduce near-term insolvency risk, so downside is more likely to come from valuation compression than a hard fundamental break.
• Set a catalyst watch for the next Sanofi update and Q4 MAH/site proceeds; if either slips, fade rallies rather than chase them because the stock’s current setup is milestone-sensitive and timing-sensitive rather than earnings-power-sensitive.